Nifty Midcap Liquid 15 News and Updates

Name: Latest research reports of Persistent Systems Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Persistent Systems Ltd.
Rating: 1
Author: Emkay

Keep track of all breaking news on Nifty Midcap Liquid 15 from all sources in a single place.

Load latest

Lupin Ltd.

25 Apr 2025

2064.40

1.21%

Lupin-led price cut slashes cost of key TB drug pretomanid by 25%

Business Line

Multiple drug price reductions bring BPaLM treatment regimen price down 47 percent, at $310, since December 2022.

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Persistent Systems Ltd.

25 Apr 2025

5761.00

-1.97%

Strong execution in a challenging environment

Sell: Persistent Systems Ltd.

Target

Emkay

PSYS reported a robust operating performance in Q4. Revenue growth of 4.5% QoQ CC was in-line, while EBITM of 15.6% was ahead of our estimate. Growth was predominantly led by BFSI and Hi-Tech while HLS stood flat.

KRChoksey upgraded Persistent Systems Ltd. to Hold with a price target of 5324.0 on 28 Apr, 2025.

Persistent Systems Ltd.

25 Apr 2025

5761.00

-1.97%

Persistent Systems (SELL): Delivers strong growth but pricey at 47x

Sell: Persistent Systems Ltd.

Target

BOB Capital Markets Ltd.

Delivers industry leading growth in FY25 and in 4QFY25 and maintains its aspiration of US$2bn revenue by FY27 (20% CAGR)

Persistent Systems Ltd. has gained 71.08% in the last 1 Year

PB Fintech Ltd.

24 Apr 2025

1714.30

0.96%

PB Fintech Invests Rs 539 Crore In Subsidiary

NDTV Profit

The investment aims to improve the subsidiary's financial stability and drive its growth objectives.

Number of FII/FPI investors increased from 957 to 977 in Mar 2025 qtr.

BSE Ltd.

24 Apr 2025

7315.50

5.18%

BSE-listed Black Box wins 1,550 crore in orders in March quarter of FY25

Business Standard

The company cited robust demand across sectors and geographies, driven by ongoing IT modernisation and digital transformation initiatives

Number of MF schemes increased from 136 to 149 in Mar 2025 qtr.

Persistent Systems Ltd.

24 Apr 2025

5761.00

-1.97%

Persistent Systems Q4 Results Review: PL Capital Upgrades The Stock To 'Buy' After Recent Correction

NDTV Profit

As the stock has witnessed sharp correction in recent times; PL Capital upgrades rating to Buy from earlier Accumulate while largely maintaining its target price.

Persistent Systems L.. has an average target of 5584.00 from 8 brokers.

Persistent Systems Q4 results: Profit rises 25% to 396 cr on strong growth

Business Standard | 24 Apr 2025 1 more

BSE Ltd.

24 Apr 2025

7315.50

5.18%

Regulations alone can't save you if you don't protect yourself: BSE CEO

Business Standard

Stressing the need for investor awareness and responsibility, BSE Managing Director and CEO Sundararaman Ramamurthy on Thursday said that regulations alone cannot protect investors if they do not take adequate precautions while investing. "You trade what you understand, and you understand what you trade if you don't do that, you have a problem," Ramamurthy said, urging investors to be vigilant and informed. He criticised the tendency of investors to rely on hearsay rather than due diligence. "You scan a vegetable before you buy it, but when you invest your life's earnings, you go by hearsay that's not how it should be," he said. On regulatory expectations, the BSE chief remarked that there is a general perception that regulators are blamed when investors lose money, but when markets do well the same person praise their own knowledge. "If you don't want to safeguard yourself, no amount of regulation can save you. Be alert," he stressed. Addressing the issue of retail participati

BSE Ltd. has gained 29.60% in the last 1 Month

Lupin Ltd.

24 Apr 2025

2064.40

1.21%

Lupin gets USFDA nod for generic kidney disease treatment drug Tolvaptan

Business Standard

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of Tolvaptan tablets indicated for a certain type of kidney disease. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, Lupin said in a regulatory filing. These are bioequivalent to Jynarque tablets in the same strengths of Otsuka Pharmaceutical Company Ltd, it added. "Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Nagpur facility and will be launched soon," the company said. Commenting on the approval, Lupin CEO Vinita Gupta said,"This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally." Tolvaptan is indicated to slow kidney function decline in .